Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 33 entries
Sorted by: Best Match Show Resources per page
Critical Review of Cost-Effectiveness Analyses (CEA) of Prevention Strategies Against Diseases Associated with Human Papillomavirus (HPV) Infection.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Gervais F, Jiang Y, Largeron N, Nikoglou T.
PMID: 27202273
Value Health. 2014 Nov;17(7):A637. doi: 10.1016/j.jval.2014.08.2288. Epub 2014 Oct 26.

No abstract available.

Cite
Gervais F, Jiang Y, Largeron N, et al. Critical Review of Cost-Effectiveness Analyses (CEA) of Prevention Strategies Against Diseases Associated with Human Papillomavirus (HPV) Infection. Value Health. 2014;17(7):A637doi: 10.1016/j.jval.2014.08.2288.
Gervais, F., Jiang, Y., Largeron, N., & Nikoglou, T. (2014). Critical Review of Cost-Effectiveness Analyses (CEA) of Prevention Strategies Against Diseases Associated with Human Papillomavirus (HPV) Infection. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A637. https://doi.org/10.1016/j.jval.2014.08.2288
Gervais, F, et al. "Critical Review of Cost-Effectiveness Analyses (CEA) of Prevention Strategies Against Diseases Associated with Human Papillomavirus (HPV) Infection." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A637. doi: https://doi.org/10.1016/j.jval.2014.08.2288
Gervais F, Jiang Y, Largeron N, Nikoglou T. Critical Review of Cost-Effectiveness Analyses (CEA) of Prevention Strategies Against Diseases Associated with Human Papillomavirus (HPV) Infection. Value Health. 2014 Nov;17(7):A637. doi: 10.1016/j.jval.2014.08.2288. Epub 2014 Oct 26. PMID: 27202273.
Copy Download .nbib Format: NLM
Detection of human cytomegalovirus and epstein-barr-virus by the polymerase chain-reaction in patients with Beta-thalassemia.

Oncology reports

Ergazaki M, Xinarianos G, Giannoudis A, Koffa M, Liloglou T, Kattamis C, Spandidos D.
PMID: 21607447
Oncol Rep. 1994 Jul;1(4):813-6. doi: 10.3892/or.1.4.813.

Infections caused by Human Cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) are common in multiple transfused patients, such as patients with beta-thalassaemia. The ability of the Polymerase Chain Reaction (PCR) to amplify HCMV and EBV DNA from blood and other...

Cite
Ergazaki M, Xinarianos G, Giannoudis A, et al. Detection of human cytomegalovirus and epstein-barr-virus by the polymerase chain-reaction in patients with Beta-thalassemia. Oncol Rep. 1994;1(4):813-6doi: 10.3892/or.1.4.813.
Ergazaki, M., Xinarianos, G., Giannoudis, A., Koffa, M., Liloglou, T., Kattamis, C., & Spandidos, D. (1994). Detection of human cytomegalovirus and epstein-barr-virus by the polymerase chain-reaction in patients with Beta-thalassemia. Oncology reports, 1(4), 813-6. https://doi.org/10.3892/or.1.4.813
Ergazaki, M, et al. "Detection of human cytomegalovirus and epstein-barr-virus by the polymerase chain-reaction in patients with Beta-thalassemia." Oncology reports vol. 1,4 (1994): 813-6. doi: https://doi.org/10.3892/or.1.4.813
Ergazaki M, Xinarianos G, Giannoudis A, Koffa M, Liloglou T, Kattamis C, Spandidos D. Detection of human cytomegalovirus and epstein-barr-virus by the polymerase chain-reaction in patients with Beta-thalassemia. Oncol Rep. 1994 Jul;1(4):813-6. doi: 10.3892/or.1.4.813. PMID: 21607447.
Copy Download .nbib Format: NLM
Inducible h-ras gene-expression controlled by an allosterically regulated transactivator.

Oncology reports

Liloglou T, Kotsinas A, Spandidos D.
PMID: 21607461
Oncol Rep. 1994 Sep;1(5):889-93. doi: 10.3892/or.1.5.889.

Inducible promoters have been employed widely to control the transcription of specific genes and thus to elucidate their role. We constructed a plasmid in which three lac operator sequences and the SV40 early promoter were placed upstream of the...

Cite
Liloglou T, Kotsinas A, Spandidos D. Inducible h-ras gene-expression controlled by an allosterically regulated transactivator. Oncol Rep. 1994;1(5):889-93doi: 10.3892/or.1.5.889.
Liloglou, T., Kotsinas, A., & Spandidos, D. (1994). Inducible h-ras gene-expression controlled by an allosterically regulated transactivator. Oncology reports, 1(5), 889-93. https://doi.org/10.3892/or.1.5.889
Liloglou, T, et al. "Inducible h-ras gene-expression controlled by an allosterically regulated transactivator." Oncology reports vol. 1,5 (1994): 889-93. doi: https://doi.org/10.3892/or.1.5.889
Liloglou T, Kotsinas A, Spandidos D. Inducible h-ras gene-expression controlled by an allosterically regulated transactivator. Oncol Rep. 1994 Sep;1(5):889-93. doi: 10.3892/or.1.5.889. PMID: 21607461.
Copy Download .nbib Format: NLM
[No title available]

Oncology letters

Al-Khafaji ASK, Marcus MW, Davies MPA, Risk JM, Shaw RJ, Field JK, Liloglou T.
PMID: 28588715
Oncol Lett. 2017 Jun;13(6):4463-4468. doi: 10.3892/ol.2017.6012. Epub 2017 Apr 07.

Deregulation of mitotic spindle genes has been reported to contribute to the development and progression of malignant tumours. The aim of the present study was to explore the association between the expression profiles of Aurora kinases (

Cite
Al-Khafaji ASK, Marcus MW, Davies MPA, et al. . Oncol Lett. 2017;13(6):4463-4468doi: 10.3892/ol.2017.6012.
Al-Khafaji, A. S. K., Marcus, M. W., Davies, M. P. A., Risk, J. M., Shaw, R. J., Field, J. K., & Liloglou, T. (2017). . Oncology letters, 13(6), 4463-4468. https://doi.org/10.3892/ol.2017.6012
Al-Khafaji, Ahmed S K, et al. "." Oncology letters vol. 13,6 (2017): 4463-4468. doi: https://doi.org/10.3892/ol.2017.6012
Al-Khafaji ASK, Marcus MW, Davies MPA, Risk JM, Shaw RJ, Field JK, Liloglou T. . Oncol Lett. 2017 Jun;13(6):4463-4468. doi: 10.3892/ol.2017.6012. Epub 2017 Apr 07. PMID: 28588715; PMCID: PMC5452881.
Copy Download .nbib Format: NLM
A long intergenic non-coding RNA regulates nuclear localization of DNA methyl transferase-1.

iScience

Jones R, Wijesinghe S, Wilson C, Halsall J, Liloglou T, Kanhere A.
PMID: 33851096
iScience. 2021 Mar 05;24(4):102273. doi: 10.1016/j.isci.2021.102273. eCollection 2021 Apr 23.

DNA methyl transferase-1 or DNMT1 maintains DNA methylation in the genome and is important for regulating gene expression in cells. Aberrant changes in DNMT1 activity and DNA methylation are commonly observed in cancers and many other diseases. Recently, a...

Cite
Jones R, Wijesinghe S, Wilson C, et al. A long intergenic non-coding RNA regulates nuclear localization of DNA methyl transferase-1. iScience. 2021;24(4):102273doi: 10.1016/j.isci.2021.102273.
Jones, R., Wijesinghe, S., Wilson, C., Halsall, J., Liloglou, T., & Kanhere, A. (2021). A long intergenic non-coding RNA regulates nuclear localization of DNA methyl transferase-1. iScience, 24(4), 102273. https://doi.org/10.1016/j.isci.2021.102273
Jones, Rhian, et al. "A long intergenic non-coding RNA regulates nuclear localization of DNA methyl transferase-1." iScience vol. 24,4 (2021): 102273. doi: https://doi.org/10.1016/j.isci.2021.102273
Jones R, Wijesinghe S, Wilson C, Halsall J, Liloglou T, Kanhere A. A long intergenic non-coding RNA regulates nuclear localization of DNA methyl transferase-1. iScience. 2021 Mar 05;24(4):102273. doi: 10.1016/j.isci.2021.102273. eCollection 2021 Apr 23. PMID: 33851096; PMCID: PMC8022221.
Copy Download .nbib Format: NLM
Rare deleterious germline variants and risk of lung cancer.

NPJ precision oncology

Liu Y, Xia J, McKay J, Tsavachidis S, Xiao X, Spitz MR, Cheng C, Byun J, Hong W, Li Y, Zhu D, Song Z, Rosenberg SM, Scheurer ME, Kheradmand F, Pikielny CW, Lusk CM, Schwartz AG, Wistuba II, Cho MH, Silverman EK, Bailey-Wilson J, Pinney SM, Anderson M, Kupert E, Gaba C, Mandal D, You M, de Andrade M, Yang P, Liloglou T, Davies MPA, Lissowska J, Swiatkowska B, Zaridze D, Mukeria A, Janout V, Holcatova I, Mates D, Stojsic J, Scelo G, Brennan P, Liu G, Field JK, Hung RJ, Christiani DC, Amos CI.
PMID: 33594163
NPJ Precis Oncol. 2021 Feb 16;5(1):12. doi: 10.1038/s41698-021-00146-7.

Recent studies suggest that rare variants exhibit stronger effect sizes and might play a crucial role in the etiology of lung cancers (LC). Whole exome plus targeted sequencing of germline DNA was performed on 1045 LC cases and 885...

Cite
Liu Y, Xia J, McKay J, et al. Rare deleterious germline variants and risk of lung cancer. NPJ Precis Oncol. 2021;5(1):12doi: 10.1038/s41698-021-00146-7.
Liu, Y., Xia, J., McKay, J., Tsavachidis, S., Xiao, X., Spitz, M. R., Cheng, C., Byun, J., Hong, W., Li, Y., Zhu, D., Song, Z., Rosenberg, S. M., Scheurer, M. E., Kheradmand, F., Pikielny, C. W., Lusk, C. M., Schwartz, A. G., Wistuba, I. I., Cho, M. H., Silverman, E. K., Bailey-Wilson, J., Pinney, S. M., Anderson, M., Kupert, E., Gaba, C., Mandal, D., You, M., de Andrade, M., Yang, P., Liloglou, T., Davies, M. P. A., Lissowska, J., Swiatkowska, B., Zaridze, D., Mukeria, A., Janout, V., Holcatova, I., Mates, D., Stojsic, J., Scelo, G., Brennan, P., Liu, G., Field, J. K., Hung, R. J., Christiani, D. C., & Amos, C. I. (2021). Rare deleterious germline variants and risk of lung cancer. NPJ precision oncology, 5(1), 12. https://doi.org/10.1038/s41698-021-00146-7
Liu, Yanhong, et al. "Rare deleterious germline variants and risk of lung cancer." NPJ precision oncology vol. 5,1 (2021): 12. doi: https://doi.org/10.1038/s41698-021-00146-7
Liu Y, Xia J, McKay J, Tsavachidis S, Xiao X, Spitz MR, Cheng C, Byun J, Hong W, Li Y, Zhu D, Song Z, Rosenberg SM, Scheurer ME, Kheradmand F, Pikielny CW, Lusk CM, Schwartz AG, Wistuba II, Cho MH, Silverman EK, Bailey-Wilson J, Pinney SM, Anderson M, Kupert E, Gaba C, Mandal D, You M, de Andrade M, Yang P, Liloglou T, Davies MPA, Lissowska J, Swiatkowska B, Zaridze D, Mukeria A, Janout V, Holcatova I, Mates D, Stojsic J, Scelo G, Brennan P, Liu G, Field JK, Hung RJ, Christiani DC, Amos CI. Rare deleterious germline variants and risk of lung cancer. NPJ Precis Oncol. 2021 Feb 16;5(1):12. doi: 10.1038/s41698-021-00146-7. PMID: 33594163; PMCID: PMC7887261.
Copy Download .nbib Format: NLM
TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

Blood

Kennedy E, Coulter E, Halliwell E, Profitos-Peleja N, Walsby E, Clark B, Phillips EH, Burley TA, Mitchell S, Devereux S, Fegan CD, Jones CI, Johnston R, Chevassut T, Schulz R, Seiffert M, Agathanggelou A, Oldreive C, Davies N, Stankovic T, Liloglou T, Pepper C, Pepper AGS.
PMID: 33512408
Blood. 2021 Jun 03;137(22):3064-3078. doi: 10.1182/blood.2020005964.

Chronic lymphocytic leukemia (CLL) remains incurable despite B-cell receptor-targeted inhibitors revolutionizing treatment. This suggests that other signaling molecules are involved in disease escape mechanisms and resistance. Toll-like receptor 9 (TLR9) is a promising candidate that is activated by unmethylated...

Cite
Kennedy E, Coulter E, Halliwell E, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021;137(22):3064-3078doi: 10.1182/blood.2020005964.
Kennedy, E., Coulter, E., Halliwell, E., Profitos-Peleja, N., Walsby, E., Clark, B., Phillips, E. H., Burley, T. A., Mitchell, S., Devereux, S., Fegan, C. D., Jones, C. I., Johnston, R., Chevassut, T., Schulz, R., Seiffert, M., Agathanggelou, A., Oldreive, C., Davies, N., Stankovic, T., Liloglou, T., Pepper, C., & Pepper, A. G. S. (2021). TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood, 137(22), 3064-3078. https://doi.org/10.1182/blood.2020005964
Kennedy, Emma, et al. "TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target." Blood vol. 137,22 (2021): 3064-3078. doi: https://doi.org/10.1182/blood.2020005964
Kennedy E, Coulter E, Halliwell E, Profitos-Peleja N, Walsby E, Clark B, Phillips EH, Burley TA, Mitchell S, Devereux S, Fegan CD, Jones CI, Johnston R, Chevassut T, Schulz R, Seiffert M, Agathanggelou A, Oldreive C, Davies N, Stankovic T, Liloglou T, Pepper C, Pepper AGS. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021 Jun 03;137(22):3064-3078. doi: 10.1182/blood.2020005964. PMID: 33512408; PMCID: PMC8176769.
Copy Download .nbib Format: NLM
ASO Visual Abstract: The Impact of Temporal Variation in Indocyanine Green Administration on Tumor Identification During Fluorescence-Guided Breast Surgery.

Annals of surgical oncology

Kedrzycki MS, Leiloglou M, Chalau V, Chiarini N, Thiruchelvam PTR, Hadjiminas DJ, Hogben KR, Rashid F, Ramakrishnan R, Darzi AW, Elson DS, Leff DR.
PMID: 34448049
Ann Surg Oncol. 2021 Dec;28:650-651. doi: 10.1245/s10434-021-10620-y.

No abstract available.

Cite
Kedrzycki MS, Leiloglou M, Chalau V, et al. ASO Visual Abstract: The Impact of Temporal Variation in Indocyanine Green Administration on Tumor Identification During Fluorescence-Guided Breast Surgery. Ann Surg Oncol. 2021;28:650-651doi: 10.1245/s10434-021-10620-y.
Kedrzycki, M. S., Leiloglou, M., Chalau, V., Chiarini, N., Thiruchelvam, P. T. R., Hadjiminas, D. J., Hogben, K. R., Rashid, F., Ramakrishnan, R., Darzi, A. W., Elson, D. S., & Leff, D. R. (2021). ASO Visual Abstract: The Impact of Temporal Variation in Indocyanine Green Administration on Tumor Identification During Fluorescence-Guided Breast Surgery. Annals of surgical oncology, 28650-651. https://doi.org/10.1245/s10434-021-10620-y
Kedrzycki, Martha S, et al. "ASO Visual Abstract: The Impact of Temporal Variation in Indocyanine Green Administration on Tumor Identification During Fluorescence-Guided Breast Surgery." Annals of surgical oncology vol. 28 (2021): 650-651. doi: https://doi.org/10.1245/s10434-021-10620-y
Kedrzycki MS, Leiloglou M, Chalau V, Chiarini N, Thiruchelvam PTR, Hadjiminas DJ, Hogben KR, Rashid F, Ramakrishnan R, Darzi AW, Elson DS, Leff DR. ASO Visual Abstract: The Impact of Temporal Variation in Indocyanine Green Administration on Tumor Identification During Fluorescence-Guided Breast Surgery. Ann Surg Oncol. 2021 Dec;28:650-651. doi: 10.1245/s10434-021-10620-y. PMID: 34448049.
Copy Download .nbib Format: NLM
Genetic variants associated with mandibular osteoradionecrosis following radiotherapy for head and neck malignancy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Brooker RC, Antczak P, Liloglou T, Risk JM, Sacco JJ, Schache AG, Shaw RJ.
PMID: 34757119
Radiother Oncol. 2021 Oct 30;165:87-93. doi: 10.1016/j.radonc.2021.10.020. Epub 2021 Oct 30.

BACKGROUND/AIM: Utilising radiotherapy in the management of head and neck cancer (HNC) often results in long term toxicities. Mandibular osteoradionecrosis (ORN) represents a late toxicity associated with significant morbidity. We aim to identify a panel of common genetic variants...

Cite
Brooker RC, Antczak P, Liloglou T, et al. Genetic variants associated with mandibular osteoradionecrosis following radiotherapy for head and neck malignancy. Radiother Oncol. 2021;165:87-93doi: 10.1016/j.radonc.2021.10.020.
Brooker, R. C., Antczak, P., Liloglou, T., Risk, J. M., Sacco, J. J., Schache, A. G., & Shaw, R. J. (2021). Genetic variants associated with mandibular osteoradionecrosis following radiotherapy for head and neck malignancy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 16587-93. https://doi.org/10.1016/j.radonc.2021.10.020
Brooker, Rachel C, et al. "Genetic variants associated with mandibular osteoradionecrosis following radiotherapy for head and neck malignancy." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 165 (2021): 87-93. doi: https://doi.org/10.1016/j.radonc.2021.10.020
Brooker RC, Antczak P, Liloglou T, Risk JM, Sacco JJ, Schache AG, Shaw RJ. Genetic variants associated with mandibular osteoradionecrosis following radiotherapy for head and neck malignancy. Radiother Oncol. 2021 Oct 30;165:87-93. doi: 10.1016/j.radonc.2021.10.020. Epub 2021 Oct 30. PMID: 34757119.
Copy Download .nbib Format: NLM
Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells.

Stem cells translational medicine

Heslop JA, Kia R, Pridgeon CS, Sison-Young RL, Liloglou T, Elmasry M, Fenwick SW, Mills JS, Kitteringham NR, Goldring CE, Park BK.
PMID: 28749066
Stem Cells Transl Med. 2017 Aug;6(8):1751. doi: 10.1002/sctm.12187. Epub 2017 Jun 15.

No abstract available.

Cite
Heslop JA, Kia R, Pridgeon CS, et al. Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells. Stem Cells Transl Med. 2017;6(8):1751doi: 10.1002/sctm.12187.
Heslop, J. A., Kia, R., Pridgeon, C. S., Sison-Young, R. L., Liloglou, T., Elmasry, M., Fenwick, S. W., Mills, J. S., Kitteringham, N. R., Goldring, C. E., & Park, B. K. (2017). Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells. Stem cells translational medicine, 6(8), 1751. https://doi.org/10.1002/sctm.12187
Heslop, James A, et al. "Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells." Stem cells translational medicine vol. 6,8 (2017): 1751. doi: https://doi.org/10.1002/sctm.12187
Heslop JA, Kia R, Pridgeon CS, Sison-Young RL, Liloglou T, Elmasry M, Fenwick SW, Mills JS, Kitteringham NR, Goldring CE, Park BK. Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells. Stem Cells Transl Med. 2017 Aug;6(8):1751. doi: 10.1002/sctm.12187. Epub 2017 Jun 15. PMID: 28749066; PMCID: PMC5689756.
Copy Download .nbib Format: NLM
H-ras oncogene mutations in the urine of patients with bladder-tumors - description of a noninvasive method for the detection of neoplasia.

International journal of oncology

Haliassos A, Liloglou T, Likourinas M, Doumas C, Ricci N, Spandidos D.
PMID: 21584608
Int J Oncol. 1992 Dec;1(7):731-4.

Bladder cancers are usually curable, by surgical or transurethral excision, if diagnosed at an early stage. Tumor derived mutations in oncogenes potentially provide specific markers for the detection of surgically resectable tumors. The detection of point mutations of H-ras...

Cite
Haliassos A, Liloglou T, Likourinas M, et al. H-ras oncogene mutations in the urine of patients with bladder-tumors - description of a noninvasive method for the detection of neoplasia. Int J Oncol. 1992;1(7):731-4
Haliassos, A., Liloglou, T., Likourinas, M., Doumas, C., Ricci, N., & Spandidos, D. (1992). H-ras oncogene mutations in the urine of patients with bladder-tumors - description of a noninvasive method for the detection of neoplasia. International journal of oncology, 1(7), 731-4.
Haliassos, A, et al. "H-ras oncogene mutations in the urine of patients with bladder-tumors - description of a noninvasive method for the detection of neoplasia." International journal of oncology vol. 1,7 (1992): 731-4.
Haliassos A, Liloglou T, Likourinas M, Doumas C, Ricci N, Spandidos D. H-ras oncogene mutations in the urine of patients with bladder-tumors - description of a noninvasive method for the detection of neoplasia. Int J Oncol. 1992 Dec;1(7):731-4. PMID: 21584608.
Copy Download .nbib Format: NLM
Allelotype of non-small cell lung cancer.

International journal of oncology

Neville E, Stewart M, Swift A, Liloglou T, Ross H, Gosney J, Donnelly R, Field J.
PMID: 21541547
Int J Oncol. 1996 Sep;9(3):533-9. doi: 10.3892/ijo.9.3.533.

Loss of heterozygosity (LOH) studies have been used extensively to identify regions on chromosomes that may contain putative tumour suppressor genes. We have undertaken extensive allelotyping of 45 specimens of non-small cell lung cancer (NSCLC) using 92 polymorphic microsatellite...

Cite
Neville E, Stewart M, Swift A, et al. Allelotype of non-small cell lung cancer. Int J Oncol. 1996;9(3):533-9doi: 10.3892/ijo.9.3.533.
Neville, E., Stewart, M., Swift, A., Liloglou, T., Ross, H., Gosney, J., Donnelly, R., & Field, J. (1996). Allelotype of non-small cell lung cancer. International journal of oncology, 9(3), 533-9. https://doi.org/10.3892/ijo.9.3.533
Neville, E, et al. "Allelotype of non-small cell lung cancer." International journal of oncology vol. 9,3 (1996): 533-9. doi: https://doi.org/10.3892/ijo.9.3.533
Neville E, Stewart M, Swift A, Liloglou T, Ross H, Gosney J, Donnelly R, Field J. Allelotype of non-small cell lung cancer. Int J Oncol. 1996 Sep;9(3):533-9. doi: 10.3892/ijo.9.3.533. PMID: 21541547.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 33 entries